Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Sarcomas
  •  Immunology
  •  Stomach Cancer
  •  Carcinomas
  •  Lung Cancers
  •  Blood Cancer
  •  Radiation Oncology
  •  Central Nervous System Tumors

Abstract

Citation: Clin Oncol. 2021;6(1):1852.DOI: 10.25107/2474-1663.1852

Performance of the EUTOS and Sokal Prognostic Scales, To Predict Optimal Response after 6 Months of Imatinib Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase

Nancy Delgado, Niels Wacher and Diana Navarrete

Deparment of Hematology, XXI Century National Medical Center, Mexico
Medical Research Unit in Clinical Epidemiology, XXI Century National Medical Center, Mexico
Blood Bank, La RAZA Medical Center Specialty Hospital, Mexico

*Correspondance to: Nancy Delgado 

 PDF  Full Text Research Article | Open Access

Abstract:

Objective: To evaluate and compare the performance of the EUTOS and Sokal prognostic scales, to predict failure to obtain cytogenetic response at 6 months, in patients with Chronic Myeloid Leukemia in chronic phase treated with imatinib, from the Hematology department of the XXI Century National Medical Center.
Material and Methods: The study included 133 adult patients, diagnosed with Chronic Myeloid Leukemia (CML) between January-2006 and July-2018. They received treatment with Imatinib and the Sokal and EUTOS scale were applied and a Complete Cytogenetic Response (CCyR) was evaluated at 6 months of treatment, to know if any of these scales had better performance.
Results: With the Sokal scale, the distribution was 36.8% low risk, 42.9% intermediate risk, and 20.3% high risk. With the EUTOS scale, 68.4% low risk and 31.6% high risk. 59.3% of patients with high risk of Sokal did not achieve CCyR at 6 months and 52.4% of patients with high risk of EUTOS, so the Sokal scale identifies a greater proportion of high-risk patients who will not achieve CCyR at 6 months. However, the difference was not statistically significant (p=0.072). In the graphic representation of the ROC Curve (at 6 months of treatment), it is observed that both prognostic scales have very similar discrimination power and the area under the curve was statistically significant. For the case of Sokal (area 0.646, p=0.005, CI 95% 0.546- 0.747) and for EUTOS (area 0.726, p=0.000, CI 95% 0.639-0.818).
Conclusion: Both scales (Sokal and EUTOS) help us to discriminate between patients who achieved CCyR at 6 months and those who did not obtain this response.

Keywords:

Sokal score; Eutos score; Chronic myeloid leukemia; Complete cytogenetic response

Cite the Article:

Delgado N, Wacher N, Navarrete D. Performance of the EUTOS and Sokal Prognostic Scales, To Predict Optimal Response after 6 Months of Imatinib Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase. Clin Oncol. 2021;6:1852..

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Identification of Ethylenediurea and Benzyl (Phenoxy) Acetic Acid Derivatives, a Potential Cocktail Therapy for Ischemia
 Abstract  PDF  Full Text
Ultrasound Strain Elastography Features in Patients with Early and Advanced Stages of Cervical Cancer
 Abstract  PDF  Full Text
View More...